Ezh2, endothelin-1, and cd34 as biomarkers of aggressive cervical squamous cell carcinoma: an immunohistochemical study

Fathy, Anan; Abdelrahman, Aziza E

doi:10.5146/tjpath.2018.01425

Cited by 6 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD34 is a transmembrane glycoprotein expressed in a vascular endothelial cell that has been used as a direct marker to highlight the microvascular density [21]. An immunohistochemical study was shown that high CD34 expression was significantly associated with tumor size, tumor stage and lymph node metastasis in cervical cancer [22]. The present study revealed a positive relationship between the pre-NACT expression of CD34 and the efficacy of NACT in cervical cancer.…”

Section: Discussionsupporting

confidence: 58%

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

Lin

Liu

et al. 2021

Arch Gynecol Obstet

View full text Add to dashboard Cite

Background Successful neoadjuvant chemotherapy (NACT) could improve the surgical resection rate and radical curability of patients with cervical cancer, but only a subset of patients benefits. Therefore, identifying predictive biomarkers are urgently needed. The aim of this study was to evaluate the predictive value of CD34 and Bcl-2 in the NACT effectiveness of cervical cancer. Methods Sixty-seven patients with locally advanced cervical cancer (FIGO stages IB3, IIA2 or IIB) were classified into two groups based on effective (n = 48) and ineffective (n = 19) response to NACT. Immunohistochemistry was employed to identify CD34 and Bcl-2 expression before and after NACT. We analyzed the associations between the pre-NACT expression of these two biomarkers and the response of NACT. The expression of these two biomarkers before and after NACT was also assessed and compared. Results More patients were CD34 positive expression before NACT in effective group compared to ineffective group (p = 0.005). However, no statistically significant difference in Bcl-2 expression before NACT were found between two groups (p = 0.084). In NACT effective group, the expression of both CD34 and Bcl-2 after NACT are down-regulated (p < 0.001 and p < 0.001, respectively), while there are no statistical differences between the pre- and post-NACT expression of CD34 and Bcl-2 in NACT ineffective group (p = 0.453 and p = 0.317, respectively). Conclusion The positive CD34 expression before NACT may serve as a predictive biomarker for NACT of cervical cancer, but the pre-NACT expression of Bcl-2 is not an independent predictor. The down-regulated expression of these two indicators after NACT may indicate effective NACT.

show abstract

Section: Discussionsupporting

confidence: 58%

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

Lin

Liu

et al. 2021

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…CD34 is a sialomucin family-related transmembrane protein that is involved in the modulation of cell adhesion and signal transduction (42). While it was first identified as a hallmark of hematopoietic stem cells, studies demonstrated that CD34 is also present on nonhematopoietic cell lines, including embryonic fibroblasts and vascular endothelial progenitors (43).…”

Section: Discussionmentioning

confidence: 99%

Cervical Cancer Stem-Like Cell Transcriptome Profiles Predict Response to Chemoradiotherapy

et al. 2021

View full text Add to dashboard Cite

Cervical cancer (CC) represents a major global health issue, particularly impacting women from resource constrained regions worldwide. Treatment refractoriness to standard chemoradiotheraphy has identified cancer stem cells as critical coordinators behind the biological mechanisms of resistance, contributing to CC recurrence. In this work, we evaluated differential gene expression in cervical cancer stem-like cells (CCSC) as biomarkers related to intrinsic chemoradioresistance in CC. A total of 31 patients with locally advanced CC and referred to Mário Penna Institute (Belo Horizonte, Brazil) from August 2017 to May 2018 were recruited for the study. Fluorescence-activated cell sorting was used to enrich CD34+/CD45- CCSC from tumor biopsies. Transcriptome was performed using ultra-low input RNA sequencing and differentially expressed genes (DEGs) using Log2 fold differences and adjusted p-value < 0.05 were determined. The analysis returned 1050 DEGs when comparing the Non-Responder (NR) (n=10) and Responder (R) (n=21) groups to chemoradiotherapy. These included a wide-ranging pattern of underexpressed coding genes in the NR vs. R patients and a panel of lncRNAs and miRNAs with implications for CC tumorigenesis. A panel of biomarkers was selected using the rank-based AUC (Area Under the ROC Curve) and pAUC (partial AUC) measurements for diagnostic sensitivity and specificity. Genes overlapping between the 21 highest AUC and pAUC loci revealed seven genes with a strong capacity for identifying NR vs. R patients (ILF2, RBM22P2, ACO16722.1, AL360175.1 and AC092354.1), of which four also returned significant survival Hazard Ratios. This study identifies DEG signatures that provide potential biomarkers in CC prognosis and treatment outcome, as well as identifies potential alternative targets for cancer therapy.

show abstract

“…CD34 is a sialomucin family-related transmembrane protein that is involved in the modulation of cell adhesion and signal transduction. 38 While it was first identified as a hallmark of hematopoietic stem cells, studies demonstrated that CD34 is also present on nonhematopoietic cell lines, including embryonic fibroblasts and vascular endothelial progenitors. 39 Here we used CD34+ CD45-to sort subpopulations of tumor cells using flow cytometry as the most effective approach towards enriching stem-like tumor cells, thereby eliminating hematopoietic stem cells which are CD34+CD45+.…”

Section: Discussionmentioning

confidence: 99%

Cervical cancer stem-like cell transcriptome profiles predict response to chemoradiotherapy

Zuccherato

Machado

Magalhães

et al. 2020

Preprint

View full text Add to dashboard Cite

Cervical cancer (CC) represents a major global health issue, particularly impacting women from resource constrained regions worldwide. Treatment refractoriness to standard chemo-radiotherapy has identified cancer stem cells as critical coordinators behind the biological mechanisms of resistance, contributing to CC recurrence. In this work, we evaluated differential gene expression in cervical cancer stem-like cells (CCSC) as biomarkers related to intrinsic chemoradioresistance in CC. A total of 31 patients with locally advanced CC and referred to Mario Penna Institute (Belo Horizonte, Brazil) from August 2017 to May 2018 were recruited for the study. Fluorescence-activated cell sorting (FACS) was used to enrich CD34+/CD45- CCSC from tumor biopsies. Transcriptome was performed using ultra-low input RNA sequencing and differentially expressed genes (DEGs) using Log2 fold differences and adjusted p value < 0.05 were determined. A panel of biomarkers was selected using the rank-based AUC (Area Under the ROC Curve) and pAUC (partial AUC) measurements for diagnostic sensitivity and specificity. The analysis showed 1062 DEGs comparing between the Non-Responder (n=10) and Responder (n=21) groups to chemoradiotherapy. Overlapping of the 20 highest AUC and pAUC values revealed five transcripts potentially implicated in innate chemoresistance (ILF2, SNX2, COPZ1, AC016722.1 and AL360175.1). This study identifies DEG signatures that serve as potential biomarkers in CC prognosis and treatment outcome, as well as identifies potential alternative targets for cancer therapy.

show abstract

Ezh2, endothelin-1, and cd34 as biomarkers of aggressive cervical squamous cell carcinoma: an immunohistochemical study

Cited by 6 publications

References 21 publications

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

CD34 and Bcl-2 as predictors for the efficacy of neoadjuvant chemotherapy in cervical cancer

Cervical Cancer Stem-Like Cell Transcriptome Profiles Predict Response to Chemoradiotherapy

Cervical cancer stem-like cell transcriptome profiles predict response to chemoradiotherapy

Contact Info

Product

Resources

About